Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Kurt J. Hilzinger acquired 17,781 shares of the company’s stock in a transaction on Tuesday, January 8th. The shares were bought at an average cost of $0.62 per share, with a total value of $11,024.22. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
OTLK opened at $0.68 on Friday. Outlook Therapeutics, Inc. has a 52 week low of $0.20 and a 52 week high of $0.80.
ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2019/01/12/outlook-therapeutics-inc-otlk-director-acquires-11024-22-in-stock.html.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Article: What is net income?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.